Liver Cancer Trial, Recruiting NCT06248554 Sponsor: Chen Xiaoping Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT06248554
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 years
  • People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) confirmed by tissue testing, at an early stage (classified as BCLC stage 0 or A)
  • People whose cancer has not spread outside the liver
  • People who showed no signs of cancer returning on imaging scans taken 2 to 4 weeks after ablation treatment (a procedure that destroys tumour tissue)
  • People who are generally able to carry out daily activities with little to no limitation (confirm with trial site for exact fitness level required)
  • People with reasonably well-functioning liver and blood test results within acceptable ranges (confirm with trial site for exact values)

Who may not be able to join:

  • People who have had any other type of cancer in the past, or whose liver cancer has come back after previous treatment
  • People who have received any treatment for liver cancer before, whether targeting the liver directly or through the whole body
  • People who have any current serious infection, an active autoimmune disease, a history of autoimmune disease, or a weakened immune system
  • People who are still experiencing serious complications from their ablation procedure
  • People who have had bleeding from varicose veins in the oesophagus or stomach within the past 6 months
  • People who are unable or unwilling to follow the treatment plan and attend required monitoring visits
  • People who are currently taking part in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: WanGuang D Zhang, Tongji Hospital

Phone: +8613886195965

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Chen Xiaoping
Registry
ClinicalTrials.gov
Start date
1 December 2019
Est. completion
31 December 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov